Methylbenzylpiperazine

Last updated
Methylbenzylpiperazine
Methylbenzylpiperazine.svg
Methylbenzylpiperazine 3d.png
Clinical data
Other names1-methyl-4-(phenylmethyl)piperazine; 1-methyl-4-benzylpiperazine
Routes of
administration
By mouth
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • II-P(Poland) [1]
Pharmacokinetic data
Metabolism liver
Excretion kidney
Identifiers
  • 1-benzyl-4-methylpiperazine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.133.648 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C12H18N2
Molar mass 190.290 g·mol−1
3D model (JSmol)
  • CN1CCN(CC1)CC2=CC=CC=C2
  • InChI=1S/C12H18N2/c1-13-7-9-14(10-8-13)11-12-5-3-2-4-6-12/h2-6H,7-11H2,1H3 X mark.svgN
  • Key:MLJOKPBESJWYGL-UHFFFAOYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Methylbenzylpiperazine (1-methyl-4-benzylpiperazine, MBZP) is a stimulant drug which is a derivative of benzylpiperazine. MBZP has been sold as an ingredient in legal recreational drugs known as "party pills", initially in New Zealand and subsequently in other countries around the world.

The effects of MBZP are very similar to those of benzylpiperazine (BZP), but the stimulant effect is slightly weaker and it seems to have less of a tendency to cause negative side effects such as headaches and nausea.[ citation needed ]

Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal. [2]

MBZP is classified as a class C drug in the UK.

In Canada MBZP remains unscheduled and uncontrolled as of January, 2015. It is not approved for any medical use but is legally available as a research chemical. MBZP is chemically closely related to the controlled Schedule III substance BZP but the latter's scheduling status shields most of its close derivatives from mandatory analogue laws which in Canada apply only to substances belonging to Schedule I under CDSA regulations, which comprises both explicitly illegal substances as well as legal drugs with the highest potential for abuse and dependence, most of which are listed as US Schedule II in the United States. Unlike the US however, stimulants widely used in the treatment of ADHD and narcolepsy in Canada are classified under Schedule III to avoid impractical administrative complications applied to the dispensing of Schedule I substances, a situation which could prompt some practitioners to abstain from dispensing the most proper treatment in order to avoid legal harassment and time-consuming record-keeping not directly related to patient care. BZP, whose abuse profile compared with ADHD treatment drugs is not documented enough to establish any correlation, nonetheless lacks the potency to qualify for Schedule I but was deemed a serious enough concern for control under Schedule III, allowing Health Canada to suspend its sale, but not that of its less potent derivatives, pending further assessment. MBZP remains uncontrolled in Canada as of 2015.

See also

Related Research Articles

<span class="mw-page-title-main">Controlled Substances Act</span> United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

<span class="mw-page-title-main">Narcotic</span> Chemical substance with psycho-active properties

The term narcotic originally referred medically to any psychoactive compound with numbing or paralyzing properties. In the United States, it has since become associated with opiates and opioids, commonly morphine and heroin, as well as derivatives of many of the compounds found within raw opium latex. The primary three are morphine, codeine, and thebaine.

<span class="mw-page-title-main">Khat</span> Psychoactive species of plant

Khat or qat, Catha edulis is a flowering plant native to eastern and southeastern Africa. It has a history of cultivation originating in the Harar area and subsequently introduced at different times to countries nearby in East Africa and Southern Arabia, most notably Yemen. Cultivated by farmers, its leaves are sold on the market to be chewed as a recreational stimulant. The world's largest consumers are Eastern Africans, particularly Somalis, and nearby Yemen; with the largest producers/exporters being Ethiopia and Kenya,

<span class="mw-page-title-main">Club drug</span> Category of recreational drugs

Club drugs, also called rave drugs or party drugs, are a loosely defined category of recreational drugs which are associated with discothèques in the 1970s and nightclubs, dance clubs, electronic dance music (EDM) parties, and raves in the 1980s to today. Unlike many other categories, such as opiates and benzodiazepines, which are established according to pharmaceutical or chemical properties, club drugs are a "category of convenience", in which drugs are included due to the locations they are consumed and/or where the user goes while under the influence of the drugs. Club drugs are generally used by adolescents and young adults.

A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids.

<span class="mw-page-title-main">Benzylpiperazine</span> Recreational drug

Benzylpiperazine (BZP) is a substance often used as a recreational drug and is known to have euphoriant and stimulant properties. Several studies conducted between 2000 and 2011 found that the effects of BZP are similar to amphetamine, although BZP's dosage is roughly 10 times higher by weight.

<span class="mw-page-title-main">Trifluoromethylphenylpiperazine</span> Chemical compound

3-Trifluoromethylphenylpiperazine (TFMPP) is a recreational drug of the phenylpiperazine chemical class and is a substituted piperazine. Usually in combination with benzylpiperazine (BZP) and other analogues, it is sold as an alternative to the illicit drug MDMA ("Ecstasy").

<span class="mw-page-title-main">Piperazine</span> Chemical compound

Piperazine is an organic compound that consists of a six-membered ring containing two nitrogen atoms at opposite positions in the ring. Piperazine exists as small alkaline deliquescent crystals with a saline taste.

The Misuse of Drugs Act 1977, the Misuse of Drugs Act 1984, Misuse of Drugs Act 2015 and the Criminal Justice Act 2010 are the acts of the Oireachtas regulating drugs in Ireland. The acts define the penalties for unlawful production, possession and supply of drugs.

<span class="mw-page-title-main">Party pills</span> Type of recreational drugs

Party pills, also known as "herbal highs", "pep pills" "dance pills" and "natural power", is a colloquialism for a type of recreational drug whose main ingredient was originally benzylpiperazine (BZP), but has expanded to a wide range of compounds with a variety of effects. BZP is banned in several countries, including the USA, Republic of Ireland, Australia and New Zealand, but is available on a more or less restricted basis in many jurisdictions. A range of other piperazine derivatives have also been sold as ingredients in party pills, and many of these branded "proprietary blends" have subsequently been sold in countries around the world.

<i>meta</i>-Chlorophenylpiperazine Stimulant

meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States.

<i>para</i>-Methoxyphenylpiperazine Chemical compound

para-Methoxyphenylpiperazine is a piperazine derivative with stimulant effects which has been sold as an ingredient in "Party pills", initially in New Zealand and subsequently in other countries around the world.

<i>para</i>-Fluorophenylpiperazine Chemical compound

para-Fluorophenylpiperazine is a piperazine derivative with mildly psychedelic and euphoriant effects. It has been sold as an ingredient in legal recreational drugs known as "Party pills", initially in New Zealand and subsequently in other countries around the world.

<span class="mw-page-title-main">Piberaline</span> Chemical compound

Piberaline is a psychoactive drug and member of the piperazine chemical class which was developed in the 1980s. It has stimulant and antidepressant effects which are thought to be due largely to its active metabolite benzylpiperazine. It was researched to a limited extent in Hungary and Spain, but was not widely accepted and does not seem to be in current use, although a closely related drug befuraline with similar effects has been slightly more successful.

<span class="mw-page-title-main">Desoxypipradrol</span> Chemical compound

Desoxypipradrol, also known as 2-⁠diphenylmethylpiperidine (2-DPMP), is a drug developed by Ciba in the 1950s which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI).

<span class="mw-page-title-main">2C-B-BZP</span> Chemical compound

4-Bromo-2,5-dimethoxy-1-benzylpiperazine (2C-B-BZP) is a psychoactive drug and research chemical of the piperazine chemical class which has been sold as a "designer drug". It produces stimulant effects similar to those of benzylpiperazine (BZP).

<span class="mw-page-title-main">Dibenzylpiperazine</span> Chemical compound

Dibenzylpiperazine (DBZP) is a piperazine derivative often found as an impurity in the recreational stimulant drug benzylpiperazine (BZP). Presence of DBZP is a marker for low quality or badly made BZP. It can be made as a reaction byproduct during BZP synthesis, either because the reaction has been run at too high a temperature, or because an excess of benzyl chloride has been used.

A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The controlled drug legislation in these jurisdictions requires drug scheduling decisions to follow an evidence-based process, where the harms of the drug are assessed and reviewed so that an appropriate legal status can be assigned. Since many designer drugs sold in recent years have had little or no published research that could help inform such a decision, they have been widely sold as "legal highs", often for months, before sufficient evidence accumulates to justify placing them on the controlled drug schedules.

Substituted piperazines are a class of chemical compounds based on a piperazine core. Some are used as recreational drugs and some are used in scientific research.

<span class="mw-page-title-main">3-Methylbenzylpiperazine</span> Chemical compound

3-Methylbenzylpiperazine (3-Me-BZP) is a stimulant drug which is a derivative of benzylpiperazine. It has been sold as a designer drug, first being identified in Sweden in February 2012.

References

  1. "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 )". Internetowy System Aktów Prawnych. Archived from the original on 27 June 2012. Retrieved 17 June 2011.
  2. Misuse of Drugs (Classification of BZP) Amendment Bill 2008